Taysha Gene Therapies (TSHA) Income towards Parent Company (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Income towards Parent Company of -$98.1 million for Q1 2026, down 243.13% on a YoY basis from $68.5 million in Q1 2025, and down 285.64% sequentially from -$25.4 million in Q4 2025.
Taysha Gene Therapies (TSHA) Income towards Parent Company (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Income towards Parent Company data on file, last reported at -$98.1 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 243.13% year-over-year to -$98.1 million; the trailing twelve-month figure through Mar 2026 stood at -$236.7 million (down 88.95% YoY), and the FY2025 full-year result was -$183.0 million, up 7.9% from the prior year.
- Income towards Parent Company fell to -$98.1 million in Q1 2026, from -$25.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$14.4 million in Q4 2024 to a low of -$98.1 million in Q1 2026.
- A 5-year average of -$40.7 million and a median of -$34.1 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 72.12% in 2023 and plunged 243.13% in 2026, its largest moves.
- Tracing TSHA's Income towards Parent Company over 5 years: stood at -$56.0 million in 2022, then soared by 72.12% to -$15.6 million in 2023, then rose by 8.06% to -$14.4 million in 2024, then sank by 77.25% to -$25.4 million in 2025, then slumped by 285.64% to -$98.1 million in 2026.
- Business Quant data shows TSHA's Income towards Parent Company at -$98.1 million in Q1 2026, -$25.4 million in Q4 2025, and -$62.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Taysha Gene Therapies | 2.05 Bn | 2.05 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.11 Mn |
| Dec 31, 2025 | -25.44 Mn |
| Sep 30, 2025 | -61.99 Mn |
| Jun 30, 2025 | -51.17 Mn |
| Mar 31, 2025 | -28.59 Mn |
| Dec 31, 2024 | -14.35 Mn |
| Sep 30, 2024 | -52.88 Mn |
| Jun 30, 2024 | -29.46 Mn |
| Mar 31, 2024 | -36.93 Mn |
| Dec 31, 2023 | -15.61 Mn |
| Sep 30, 2023 | -26.04 Mn |
| Jun 30, 2023 | -55.53 Mn |
| Mar 31, 2023 | -28.18 Mn |
| Dec 31, 2022 | -56.01 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -34.12 Mn |
| Mar 31, 2022 | -50.63 Mn |
| Dec 31, 2021 | -75.24 Mn |
| Sep 30, 2021 | -51.22 Mn |
| Jun 30, 2021 | -45.27 Mn |